Madrigal’s efforts for resmetirom will set tone for future launches of NASH therapies: GlobalData EP News Bureau Dec 7, 2023 In December 2022, the company successfully concluded raising a total of $309 million following positive topline data from the…
Madrigal drug meets main goals in much-awaited NASH trial Reuters Dec 20, 2022 The positive data sets the stage for the drug, resmetirom, to become the first treatment for NASH
